$VRDN News

Viridian Therapeutics Strikes Commercial Manufacturing Services Agreement With WuXi Biologics To Produce, Supply Veligrotug Drug Substance, Drug Product

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow

Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising

Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $34

Viridian Therapeutics’ stock up 35% after Phase III TED data release

Viridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TED

Viridian (VRDN) Climbs 33% on Looming Drug Commercialization

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market

Viridian Therapeutics Q1 EPS $(0.90) Beats $(1.05) Estimate, Sales $141.000K Beat $27.500K Estimate

Viridian Therapeutics Elegrobart Achieves 50-54% Proptosis And 61% Diplopia Responder Rates In Phase 3 REVEAL-2, Becoming Only Subcutaneous Program With Two Positive TED Pivotal Trials